APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oncolytic Virus Service

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Oncolytic Virus Service Market Analysis and Forecast 2026-2032

2 May 2026211 pages

Choose your research edition.

Industry ResearchOncolytic Virus Service Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncolytic Virus Service Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Oncolytic Virus Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncolytic Virus Service Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncolytic Virus Service Market Analysis and Forecast 2026-2032211 pages · $4,950 USD

Market perspective

The global Oncolytic Virus Service market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Oncolytic Virus Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Oncolytic Virus Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Oncolytic Virus Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Oncolytic Virus Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Oncolytic Virus Service include Creative Biolabs, Creative Biogene, Recipharm, Nabios, IDT Biologika, FUJIFILM Diosynth Biotechnologies, Exothera, Lonza and ABL, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Oncolytic Virus Service, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Oncolytic Virus Service, also provides the revenue of main regions and countries. Of the upcoming market potential for Oncolytic Virus Service, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oncolytic Virus Service revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Oncolytic Virus Service market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Oncolytic Virus Service revenue, projected growth trends, production technology, application and end-user industry.

Oncolytic Virus Service Segment by Company

Creative Biolabs

Creative Biogene

Recipharm

Nabios

IDT Biologika

FUJIFILM Diosynth Biotechnologies

Exothera

Lonza

ABL

Takara Bio

Libentech

Oncolytic Virus Service Segment by Type

Measles Virus (MeV)

Herpes Simplex Virus (HSV-1)

Others

Oncolytic Virus Service Segment by Application

Tumor Treatment

Scientific Research

Oncolytic Virus Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncolytic Virus Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncolytic Virus Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncolytic Virus Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Oncolytic Virus Service in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Oncolytic Virus Service company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncolytic Virus Service revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oncolytic Virus Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Measles Virus (MeV) Major Player Table 3. Herpes Simplex Virus (HSV-1) Major Player Table 4. Others Major Player Table 5. Global Oncolytic Virus Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Tumor Treatment Major Player Table 7. Scientific Research Major Player Table 8. Oncolytic Virus Service Industry Trends Table 9. Oncolytic Virus Service Industry Drivers Table 10. Oncolytic Virus Service Industry Opportunities and Challenges Table 11. Oncolytic Virus Service Industry Restraints Table 12. Global Oncolytic Virus Service Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Oncolytic Virus Service Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Oncolytic Virus Service Market Share by Region (2021-2026) Table 15. Global Oncolytic Virus Service Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Oncolytic Virus Service Market Share by Region (2027-2032) Table 17. Global Oncolytic Virus Service Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Oncolytic Virus Service Revenue Market Share by Players (2021-2026) Table 19. Global Oncolytic Virus Service Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Oncolytic Virus Service Key Players Headquarters & Area Served Table 21. Global Oncolytic Virus Service Players, Product Type & Application Table 22. Global Oncolytic Virus Service Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Oncolytic Virus Service by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Oncolytic Virus Service Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Oncolytic Virus Service Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Oncolytic Virus Service Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Oncolytic Virus Service Revenue Market Share by Type (2021-2026) Table 29. Global Oncolytic Virus Service Revenue Market Share by Type (2027-2032) Table 30. Global Oncolytic Virus Service Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Oncolytic Virus Service Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Oncolytic Virus Service Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Oncolytic Virus Service Revenue Market Share by Application (2021-2026) Table 34. Global Oncolytic Virus Service Revenue Market Share by Application (2027-2032) Table 35. Creative Biolabs Company Information Table 36. Creative Biolabs Business Overview Table 37. Creative Biolabs Oncolytic Virus Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Creative Biolabs Oncolytic Virus Service Product Portfolio Table 39. Creative Biolabs Recent Development Table 40. Creative Biogene Company Information Table 41. Creative Biogene Business Overview Table 42. Creative Biogene Oncolytic Virus Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Creative Biogene Oncolytic Virus Service Product Portfolio Table 44. Creative Biogene Recent Development Table 45. Recipharm Company Information Table 46. Recipharm Business Overview Table 47. Recipharm Oncolytic Virus Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Recipharm Oncolytic Virus Service Product Portfolio Table 49. Recipharm Recent Development Table 50. Nabios Company Information Table 51. Nabios Business Overview Table 52. Nabios Oncolytic Virus Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Nabios Oncolytic Virus Service Product Portfolio Table 54. Nabios Recent Development Table 55. IDT Biologika Company Information Table 56. IDT Biologika Business Overview Table 57. IDT Biologika Oncolytic Virus Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. IDT Biologika Oncolytic Virus Service Product Portfolio Table 59. IDT Biologika Recent Development Table 60. FUJIFILM Diosynth Biotechnologies Company Information Table 61. FUJIFILM Diosynth Biotechnologies Business Overview Table 62. FUJIFILM Diosynth Biotechnologies Oncolytic Virus Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. FUJIFILM Diosynth Biotechnologies Oncolytic Virus Service Product Portfolio Table 64. FUJIFILM Diosynth Biotechnologies Recent Development Table 65. Exothera Company Information Table 66. Exothera Business Overview Table 67. Exothera Oncolytic Virus Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Exothera Oncolytic Virus Service Product Portfolio Table 69. Exothera Recent Development Table 70. Lonza Company Information Table 71. Lonza Business Overview Table 72. Lonza Oncolytic Virus Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Lonza Oncolytic Virus Service Product Portfolio Table 74. Lonza Recent Development Table 75. ABL Company Information Table 76. ABL Business Overview Table 77. ABL Oncolytic Virus Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. ABL Oncolytic Virus Service Product Portfolio Table 79. ABL Recent Development Table 80. Takara Bio Company Information Table 81. Takara Bio Business Overview Table 82. Takara Bio Oncolytic Virus Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Takara Bio Oncolytic Virus Service Product Portfolio Table 84. Takara Bio Recent Development Table 85. Libentech Company Information Table 86. Libentech Business Overview Table 87. Libentech Oncolytic Virus Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 88. Libentech Oncolytic Virus Service Product Portfolio Table 89. Libentech Recent Development Table 90. North America Oncolytic Virus Service Revenue by Type (2021-2026) & (US$ Million) Table 91. North America Oncolytic Virus Service Revenue by Type (2027-2032) & (US$ Million) Table 92. North America Oncolytic Virus Service Revenue by Application (2021-2026) & (US$ Million) Table 93. North America Oncolytic Virus Service Revenue by Application (2027-2032) & (US$ Million) Table 94. North America Oncolytic Virus Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. North America Oncolytic Virus Service Revenue by Country (2021-2026) & (US$ Million) Table 96. North America Oncolytic Virus Service Revenue by Country (US$ Million) & (2027-2032) Table 97. Europe Oncolytic Virus Service Revenue by Type (2021-2026) & (US$ Million) Table 98. Europe Oncolytic Virus Service Revenue by Type (2027-2032) & (US$ Million) Table 99. Europe Oncolytic Virus Service Revenue by Application (2021-2026) & (US$ Million) Table 100. Europe Oncolytic Virus Service Revenue by Application (2027-2032) & (US$ Million) Table 101. Europe Oncolytic Virus Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 102. Europe Oncolytic Virus Service Revenue by Country (2021-2026) & (US$ Million) Table 103. Europe Oncolytic Virus Service Revenue by Country (US$ Million) & (2027-2032) Table 104. China Oncolytic Virus Service Revenue by Type (2021-2026) & (US$ Million) Table 105. China Oncolytic Virus Service Revenue by Type (2027-2032) & (US$ Million) Table 106. China Oncolytic Virus Service Revenue by Application (2021-2026) & (US$ Million) Table 107. China Oncolytic Virus Service Revenue by Application (2027-2032) & (US$ Million) Table 108. Asia Oncolytic Virus Service Revenue by Type (2021-2026) & (US$ Million) Table 109. Asia Oncolytic Virus Service Revenue by Type (2027-2032) & (US$ Million) Table 110. Asia Oncolytic Virus Service Revenue by Application (2021-2026) & (US$ Million) Table 111. Asia Oncolytic Virus Service Revenue by Application (2027-2032) & (US$ Million) Table 112. Asia Oncolytic Virus Service Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 113. Asia Oncolytic Virus Service Revenue by Region (US$ Million) & (2021-2026) Table 114. Asia Oncolytic Virus Service Revenue by Region (US$ Million) & (2027-2032) Table 115. SAMEA Oncolytic Virus Service Revenue by Type (2021-2026) & (US$ Million) Table 116. SAMEA Oncolytic Virus Service Revenue by Type (2027-2032) & (US$ Million) Table 117. SAMEA Oncolytic Virus Service Revenue by Application (2021-2026) & (US$ Million) Table 118. SAMEA Oncolytic Virus Service Revenue by Application (2027-2032) & (US$ Million) Table 119. SAMEA Oncolytic Virus Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. SAMEA Oncolytic Virus Service Revenue by Country (2021-2026) & (US$ Million) Table 121. SAMEA Oncolytic Virus Service Revenue by Country (US$ Million) & (2027-2032) Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Oncolytic Virus Service Image Figure 2. Global Oncolytic Virus Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oncolytic Virus Service Market Size Share 2021 VS 2025 VS 2032 Figure 4. Measles Virus (MeV) Image Figure 5. Herpes Simplex Virus (HSV-1) Image Figure 6. Others Image Figure 7. Global Oncolytic Virus Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Oncolytic Virus Service Market Size Share 2021 VS 2025 VS 2032 Figure 9. Tumor Treatment Image Figure 10. Scientific Research Image Figure 11. Global Oncolytic Virus Service Market Size (US$ Million) & (2021-2032) Figure 12. Global Oncolytic Virus Service Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Oncolytic Virus Service Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Oncolytic Virus Service Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Oncolytic Virus Service Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Oncolytic Virus Service Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Oncolytic Virus Service Revenue Market Share by Type (2021-2032) Figure 19. Global Oncolytic Virus Service Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Oncolytic Virus Service Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Oncolytic Virus Service Revenue Market Share by Application (2021-2032) Figure 22. North America Oncolytic Virus Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Oncolytic Virus Service Revenue Share by Type (2021-2032) Figure 24. North America Oncolytic Virus Service Revenue Share by Application (2021-2032) Figure 25. North America Oncolytic Virus Service Revenue Share by Country (2021-2032) Figure 26. United States Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Oncolytic Virus Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Oncolytic Virus Service Revenue Share by Type (2021-2032) Figure 31. Europe Oncolytic Virus Service Revenue Share by Application (2021-2032) Figure 32. Europe Oncolytic Virus Service Revenue Share by Country (2021-2032) Figure 33. Germany Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Oncolytic Virus Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Oncolytic Virus Service Revenue Share by Type (2021-2032) Figure 43. China Oncolytic Virus Service Revenue Share by Application (2021-2032) Figure 44. Asia Oncolytic Virus Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Oncolytic Virus Service Revenue Share by Type (2021-2032) Figure 46. Asia Oncolytic Virus Service Revenue Share by Application (2021-2032) Figure 47. Asia Oncolytic Virus Service Revenue Share by Region (2021-2032) Figure 48. Japan Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Oncolytic Virus Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Oncolytic Virus Service Revenue Share by Type (2021-2032) Figure 56. SAMEA Oncolytic Virus Service Revenue Share by Application (2021-2032) Figure 57. SAMEA Oncolytic Virus Service Revenue Share by Country (2021-2032) Figure 58. Brazil Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Oncolytic Virus Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Measles Virus (MeV)
  • Herpes Simplex Virus (HSV-1)
  • Others
Applications
  • Tumor Treatment
  • Scientific Research
Companies covered
  • Creative Biolabs
  • Creative Biogene
  • Recipharm
  • Nabios
  • IDT Biologika
  • FUJIFILM Diosynth Biotechnologies
  • Exothera
  • Lonza
  • ABL
  • Takara Bio
  • Libentech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Oncolytic Virus Service Market by Type
  3. 1.2.1 Global Oncolytic Virus Service Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Measles Virus (MeV)
  5. 1.2.3 Herpes Simplex Virus (HSV-1)
  6. 1.2.4 Others
  7. 1.3 Oncolytic Virus Service Market by Application
  8. 1.3.1 Global Oncolytic Virus Service Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Tumor Treatment
  10. 1.3.3 Scientific Research
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Oncolytic Virus Service Market Dynamics
  1. 2.1 Oncolytic Virus Service Industry Trends
  2. 2.2 Oncolytic Virus Service Industry Drivers
  3. 2.3 Oncolytic Virus Service Industry Opportunities and Challenges
  4. 2.4 Oncolytic Virus Service Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Oncolytic Virus Service Market Perspective (2021-2032)
  2. 3.2 Global Oncolytic Virus Service Growth Trends by Region
  3. 3.2.1 Global Oncolytic Virus Service Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Oncolytic Virus Service Market Size by Region (2021-2026)
  5. 3.2.3 Global Oncolytic Virus Service Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Oncolytic Virus Service Revenue by Players
  2. 4.1.1 Global Oncolytic Virus Service Revenue by Players (2021-2026)
  3. 4.1.2 Global Oncolytic Virus Service Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Oncolytic Virus Service Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Oncolytic Virus Service Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Oncolytic Virus Service Key Players Headquarters & Area Served
  7. 4.4 Global Oncolytic Virus Service Players, Product Type & Application
  8. 4.5 Global Oncolytic Virus Service Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Oncolytic Virus Service Market CR5 and HHI
  11. 4.6.3 2025 Oncolytic Virus Service Tier 1, Tier 2, and Tier 3
5 Oncolytic Virus Service Market Size by Type
  1. 5.1 Global Oncolytic Virus Service Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Oncolytic Virus Service Revenue by Type (2021-2032)
  3. 5.3 Global Oncolytic Virus Service Revenue Market Share by Type (2021-2032)
6 Oncolytic Virus Service Market Size by Application
  1. 6.1 Global Oncolytic Virus Service Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Oncolytic Virus Service Revenue by Application (2021-2032)
  3. 6.3 Global Oncolytic Virus Service Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Creative Biolabs
  2. 7.1.1 Creative Biolabs Company Information
  3. 7.1.2 Creative Biolabs Business Overview
  4. 7.1.3 Creative Biolabs Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Creative Biolabs Oncolytic Virus Service Product Portfolio
  6. 7.1.5 Creative Biolabs Recent Developments
  7. 7.2 Creative Biogene
  8. 7.2.1 Creative Biogene Company Information
  9. 7.2.2 Creative Biogene Business Overview
  10. 7.2.3 Creative Biogene Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Creative Biogene Oncolytic Virus Service Product Portfolio
  12. 7.2.5 Creative Biogene Recent Developments
  13. 7.3 Recipharm
  14. 7.3.1 Recipharm Company Information
  15. 7.3.2 Recipharm Business Overview
  16. 7.3.3 Recipharm Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Recipharm Oncolytic Virus Service Product Portfolio
  18. 7.3.5 Recipharm Recent Developments
  19. 7.4 Nabios
  20. 7.4.1 Nabios Company Information
  21. 7.4.2 Nabios Business Overview
  22. 7.4.3 Nabios Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Nabios Oncolytic Virus Service Product Portfolio
  24. 7.4.5 Nabios Recent Developments
  25. 7.5 IDT Biologika
  26. 7.5.1 IDT Biologika Company Information
  27. 7.5.2 IDT Biologika Business Overview
  28. 7.5.3 IDT Biologika Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  29. 7.5.4 IDT Biologika Oncolytic Virus Service Product Portfolio
  30. 7.5.5 IDT Biologika Recent Developments
  31. 7.6 FUJIFILM Diosynth Biotechnologies
  32. 7.6.1 FUJIFILM Diosynth Biotechnologies Company Information
  33. 7.6.2 FUJIFILM Diosynth Biotechnologies Business Overview
  34. 7.6.3 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  35. 7.6.4 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Service Product Portfolio
  36. 7.6.5 FUJIFILM Diosynth Biotechnologies Recent Developments
  37. 7.7 Exothera
  38. 7.7.1 Exothera Company Information
  39. 7.7.2 Exothera Business Overview
  40. 7.7.3 Exothera Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Exothera Oncolytic Virus Service Product Portfolio
  42. 7.7.5 Exothera Recent Developments
  43. 7.8 Lonza
  44. 7.8.1 Lonza Company Information
  45. 7.8.2 Lonza Business Overview
  46. 7.8.3 Lonza Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Lonza Oncolytic Virus Service Product Portfolio
  48. 7.8.5 Lonza Recent Developments
  49. 7.9 ABL
  50. 7.9.1 ABL Company Information
  51. 7.9.2 ABL Business Overview
  52. 7.9.3 ABL Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  53. 7.9.4 ABL Oncolytic Virus Service Product Portfolio
  54. 7.9.5 ABL Recent Developments
  55. 7.10 Takara Bio
  56. 7.10.1 Takara Bio Company Information
  57. 7.10.2 Takara Bio Business Overview
  58. 7.10.3 Takara Bio Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Takara Bio Oncolytic Virus Service Product Portfolio
  60. 7.10.5 Takara Bio Recent Developments
  61. 7.11 Libentech
  62. 7.11.1 Libentech Company Information
  63. 7.11.2 Libentech Business Overview
  64. 7.11.3 Libentech Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Libentech Oncolytic Virus Service Product Portfolio
  66. 7.11.5 Libentech Recent Developments
8 North America
  1. 8.1 North America Oncolytic Virus Service Revenue (2021-2032)
  2. 8.2 North America Oncolytic Virus Service Revenue by Type (2021-2032)
  3. 8.2.1 North America Oncolytic Virus Service Revenue by Type (2021-2026)
  4. 8.2.2 North America Oncolytic Virus Service Revenue by Type (2027-2032)
  5. 8.3 North America Oncolytic Virus Service Revenue Share by Type (2021-2032)
  6. 8.4 North America Oncolytic Virus Service Revenue by Application (2021-2032)
  7. 8.4.1 North America Oncolytic Virus Service Revenue by Application (2021-2026)
  8. 8.4.2 North America Oncolytic Virus Service Revenue by Application (2027-2032)
  9. 8.5 North America Oncolytic Virus Service Revenue Share by Application (2021-2032)
  10. 8.6 North America Oncolytic Virus Service Revenue by Country
  11. 8.6.1 North America Oncolytic Virus Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Oncolytic Virus Service Revenue by Country (2021-2026)
  13. 8.6.3 North America Oncolytic Virus Service Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Oncolytic Virus Service Revenue (2021-2032)
  2. 9.2 Europe Oncolytic Virus Service Revenue by Type (2021-2032)
  3. 9.2.1 Europe Oncolytic Virus Service Revenue by Type (2021-2026)
  4. 9.2.2 Europe Oncolytic Virus Service Revenue by Type (2027-2032)
  5. 9.3 Europe Oncolytic Virus Service Revenue Share by Type (2021-2032)
  6. 9.4 Europe Oncolytic Virus Service Revenue by Application (2021-2032)
  7. 9.4.1 Europe Oncolytic Virus Service Revenue by Application (2021-2026)
  8. 9.4.2 Europe Oncolytic Virus Service Revenue by Application (2027-2032)
  9. 9.5 Europe Oncolytic Virus Service Revenue Share by Application (2021-2032)
  10. 9.6 Europe Oncolytic Virus Service Revenue by Country
  11. 9.6.1 Europe Oncolytic Virus Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Oncolytic Virus Service Revenue by Country (2021-2026)
  13. 9.6.3 Europe Oncolytic Virus Service Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Oncolytic Virus Service Revenue (2021-2032)
  2. 10.2 China Oncolytic Virus Service Revenue by Type (2021-2032)
  3. 10.2.1 China Oncolytic Virus Service Revenue by Type (2021-2026)
  4. 10.2.2 China Oncolytic Virus Service Revenue by Type (2027-2032)
  5. 10.3 China Oncolytic Virus Service Revenue Share by Type (2021-2032)
  6. 10.4 China Oncolytic Virus Service Revenue by Application (2021-2032)
  7. 10.4.1 China Oncolytic Virus Service Revenue by Application (2021-2026)
  8. 10.4.2 China Oncolytic Virus Service Revenue by Application (2027-2032)
  9. 10.5 China Oncolytic Virus Service Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Oncolytic Virus Service Revenue (2021-2032)
  2. 11.2 Asia Oncolytic Virus Service Revenue by Type (2021-2032)
  3. 11.2.1 Asia Oncolytic Virus Service Revenue by Type (2021-2026)
  4. 11.2.2 Asia Oncolytic Virus Service Revenue by Type (2027-2032)
  5. 11.3 Asia Oncolytic Virus Service Revenue Share by Type (2021-2032)
  6. 11.4 Asia Oncolytic Virus Service Revenue by Application (2021-2032)
  7. 11.4.1 Asia Oncolytic Virus Service Revenue by Application (2021-2026)
  8. 11.4.2 Asia Oncolytic Virus Service Revenue by Application (2027-2032)
  9. 11.5 Asia Oncolytic Virus Service Revenue Share by Application (2021-2032)
  10. 11.6 Asia Oncolytic Virus Service Revenue by Country
  11. 11.6.1 Asia Oncolytic Virus Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Oncolytic Virus Service Revenue by Country (2021-2026)
  13. 11.6.3 Asia Oncolytic Virus Service Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Oncolytic Virus Service Revenue (2021-2032)
  2. 12.2 SAMEA Oncolytic Virus Service Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Oncolytic Virus Service Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Oncolytic Virus Service Revenue by Type (2027-2032)
  5. 12.3 SAMEA Oncolytic Virus Service Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Oncolytic Virus Service Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Oncolytic Virus Service Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Oncolytic Virus Service Revenue by Application (2027-2032)
  9. 12.5 SAMEA Oncolytic Virus Service Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Oncolytic Virus Service Revenue by Country
  11. 12.6.1 SAMEA Oncolytic Virus Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Oncolytic Virus Service Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Oncolytic Virus Service Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst